What is the story about?
What's Happening?
Psilera Inc., a biotechnology company based in Tampa, Florida, has secured a $2 million grant from the National Institutes of Health (NIH) to advance research on Alcohol Use Disorder (AUD). The grant, awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), will support the development of a novel neuroplastogen as a potential treatment for AUD. Psilera's research focuses on compounds that reshape neuronal pathways in the brain, offering a non-opioid treatment alternative for alcohol consumption. The company's approach leverages its Third Eye™ platform to identify promising compounds targeting the serotonin receptor 5-HT2A, with the goal of providing a non-hallucinogenic and non-addictive treatment option for AUD patients.
Why It's Important?
The NIH grant represents a significant endorsement of Psilera's innovative approach to treating AUD, a condition affecting nearly 30 million adults in the U.S. With only a small percentage of patients currently seeking treatment, there is a substantial unmet need for effective therapies. Psilera's research into neuroplastogens could revolutionize the treatment landscape for AUD, offering a safer and more accessible option for patients. If successful, this new therapy could reduce the stigma and barriers associated with AUD treatment, potentially improving patient outcomes and public health. The grant also highlights the growing interest in psychedelic-inspired therapies for mental health and addiction disorders.
AI Generated Content
Do you find this article useful?
